Literature DB >> 22632364

Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease.

John H Lazarus1.   

Abstract

The incidence of Graves' orbitopathy (GO) is 16/100,000 in females and 2.9/100,000 in males as studied in Olmsted county. It can be calculated that the approximate prevalence is 0.25%. There is a gender bimodal distribution. Go usually occurs at the time of onset of the hyperthyroidism but may present up to a year before that time or as long as 5 years afterwards. Around 10-15% of patients have never been hyperthyroid and some are hypothyroid at GO presentation. Although the incidence of GO has probably been decreasing during the last 2 decades definite figures for this assertion are not available. Risk factors that may influence the incidence of GO include cigarette smoking and radioiodine treatment of hyperthyroidism. There are also complex genetic factors with multiple susceptibility alleles that contribute to the expression of the disease. The probability is that a reduction of the incidence of GO will be achieved by influencing the environmental factors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22632364     DOI: 10.1016/j.beem.2011.10.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  42 in total

Review 1.  The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy.

Authors:  Yang Wang; Huifang Zhou; Xianqun Fan
Journal:  Front Med       Date:  2017-05-13       Impact factor: 4.592

Review 2.  "Orbiting around" the orbital myositis: clinical features, differential diagnosis and therapy.

Authors:  F Montagnese; S Wenninger; B Schoser
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

Review 3.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

4.  Outcomes of endoscopic orbital decompression for graves' ophthalmopathy.

Authors:  Robbie S R Woods; Qistina Pilson; Natallia Kharytaniuk; Lorraine Cassidy; Rizwana Khan; Conrad V I Timon
Journal:  Ir J Med Sci       Date:  2019-06-16       Impact factor: 1.568

5.  Assessment of Orbital Computed Tomography (CT) Imaging Biomarkers in Patients with Thyroid Eye Disease.

Authors:  Shikha Chaganti; Kevin Mundy; Michael P DeLisi; Katrina M Nelson; Robert L Harrigan; Robert L Galloway; Bennett A Landman; Louise A Mawn
Journal:  J Digit Imaging       Date:  2019-12       Impact factor: 4.056

Review 6.  2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.

Authors:  Ilaria Muller; Carla Moran; Beatriz Lecumberri; Brigitte Decallonne; Neil Robertson; Joanne Jones; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2019-07-04

7.  Neuroanatomic Variations in Graves' Dysthyroid Ophthalmopathy as Studied With MRI.

Authors:  Rona Z Silkiss; Alex R Wade
Journal:  Trans Am Ophthalmol Soc       Date:  2017-05-24

Review 8.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

9.  [Update on endocrine orbitopathy].

Authors:  A Eckstein; U Berchner-Pfannschmidt; D Führer; J Esser
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

10.  BIOINFORMATIC ANALYSIS IDENTIFIES POTENTIALLY KEY DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS IN ORBITAL ADIPOSE TISSUES OF PATIENTS WITH THYROID EYE DISEASE.

Authors:  F F Zhu; L Z Yang
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.